- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02070562
Human Milk Profiles and Dietary Intake of Chinese Lactating Mothers During Early Lactation Period in Shanghai (MuRu)
5. februar 2015 opdateret af: Dumex Baby Food Co., Ltd.
This study aims to investigate breast milk composition and dietary habits of Chinese lactating mothers.
Further understanding of the composition of human milk will help to understand the nutritional needs of mothers and their infants in their early phase of life which eventually will help to support breastfeeding.
Studieoversigt
Status
Ukendt
Betingelser
Undersøgelsestype
Observationel
Tilmelding (Forventet)
120
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Shanghai, Kina
- Shanghai Children's Medical Center
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
20 år til 40 år (Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Kvinde
Prøveudtagningsmetode
Sandsynlighedsprøve
Studiebefolkning
General health lactating mothers
Beskrivelse
Inclusion Criteria:
- Generally healthy mothers who give birth to a healthy term infant (37-42 weeks) whose birth weight is >10 and <90 percentiles gestational birth weight chart.
- Aged 20 - 40 years.
- Mothers who intend to exclusively breastfeed the infant for more than 6 weeks.
- Chinese ethnicity, including both parents.
- Mothers who sign the informed consent form in writing.
Exclusion Criteria:
Mothers:
- Participation in any other studies involving investigational or marketed products concomitantly or two weeks prior to entry into the study.
- Difficult to follow up and/or locate (e.g. known transfer to other hospitals, residing outside Shanghai, plan to move out of Shanghai).
- Current smoker or having smoked during the pregnancy.
- Having consumed alcoholic drinks during pregnancy or lactation.
- Illegal drug abuser: cannabinoids (marijuana, hashish), stimulants (cocaine, amphetamine, methamphetamine), opioid (heroin, opium).
- Acute infection disease or neoplastic disease or any kind of weakening or debilitating conditions (no history of positive HBV, HCV or HIV serological test at any time during the pregnancy).
- Use of drug or pharmacologically active substances (e.g. herbal products, traditional medicine) to treat a particular disease or medical condition from the beginning of lactation ( those who consume herbal/traditional medicine for maintaining or improving well-being will still be included).
- Presence of mastitis, fungal infections of the nipple or areola; reactivation of herpes simplex (HSV) or varicella zoster infection in the mammary or thoracic region at the time of enrolment.
- Presence of endocrinology diseases, particularly diabetes mellitus and gestational diabetes.
- Presence of obesity (pre-pregnancy BMI > 28).
- Presence of chronic diseases such as cardiovascular, renal, respiratory and hepatic diseases.
- Presence of psychosis and severe post-partum depression.
- Presence of autoimmune disease such as systemic lupus erythematosus, systemic scleroderma, ulcerative colitis, Crohn's disease, celiac disease.
- Women whose health condition, according to the investigator's judgement, could interfere with the study conduct and assessment.
- Mothers who have given birth to twins or multiples or infant conceived with Assisted Reproductive Technology (ART).
- Elimination diet due to chronic allergic diseases or vegan.
- Incapability of subject to comply with study protocol or investigator's uncertainty about the willingness or ability of the mothers to understand and comply with the protocol requirements.
Infants:
- Any congenital abnormality, chromosomal disorder or severe disease which could interfere with the study conduct and assessment.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Community Group
Chinese lactating mothers from community maternal & child healthcare centre
|
|
VIP Group
Chinese lactating mothers from VIP clinics (maternal care center)
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Breast milk composition
Tidsramme: 0-42 day postpartum
|
Human milk oligosaccharides profiles, fatty acids profile, macronutrients and energy content will be measured.
|
0-42 day postpartum
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Growth
Tidsramme: 0-42 day postpartum
|
Infant's anthropometrics (weight, length, head circumference).
|
0-42 day postpartum
|
|
Maternal diet survey
Tidsramme: 0-42 day postpartum
|
Dietary macronutrients and energy intake, and food patterns will be assessed.
|
0-42 day postpartum
|
|
Infection
Tidsramme: 0-42 day postpartum
|
Parent-reported infection patterns of infants during the observation period.
|
0-42 day postpartum
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Jing Li, professor, Shanghai Children's Medical Center Affiliated Shanghai Jiao Tong University, School of Medicine
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. februar 2014
Primær færdiggørelse (Forventet)
1. august 2015
Studieafslutning (Forventet)
1. juni 2016
Datoer for studieregistrering
Først indsendt
27. januar 2014
Først indsendt, der opfyldte QC-kriterier
23. februar 2014
Først opslået (Skøn)
25. februar 2014
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
9. februar 2015
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
5. februar 2015
Sidst verificeret
1. februar 2015
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- HMR.1.C/A
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Modermælk
-
USDA, Western Human Nutrition Research CenterUniversity of Copenhagen; Bill and Melinda Gates Foundation; International... og andre samarbejdspartnereRekrutteringHuman Milk Nutrient Reference VærdierDanmark, Bangladesh, Brasilien, Gambia
-
Cairo UniversityIkke rekrutterer endnu
-
The First Affiliated Hospital of Xiamen UniversityIkke rekrutterer endnuLocally Advanced Breast Cancer (LABC)
-
Abouqir General HospitalAlexandria UniversityRekrutteringBreast Udseende Rekonstruktion DisproportionEgypten
-
Beijing Bio-Targeting Therapeutics Technology Co...Trukket tilbage
-
Nutricia ResearchAfsluttetVækst | Tolerance | Sikkerhed | Emner, der har brug for en Human Milk Fortifier (HMF)Holland, Frankrig, Tyskland, Det Forenede Kongerige
-
Indonesia UniversityIkke rekrutterer endnuPræhabilitering | Postoperativ inflammation | Locally Advanced Breast Cancer (LABC)Indonesien
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnereAfsluttetDen kliniske anvendelsesvejledning af Conebeam Breast CTKina
-
Atlas UniversityIkke rekrutterer endnuBrystkræft | Locally Advanced Breast Cancer (LABC)Tyrkiet (Türkiye)
-
ETOP IBCSG Partners FoundationAfsluttetBreast Cancer Invasive NosItalien